MT Højgaard Holding A/S
8.3.2021 13:41:38 CET | Globenewswire | Press release
On 23 November 2020, MT Højgaard Holding A/S announced that a share buy-back programme of an aggregated price of up to DKK 15,000,000 was launched with the purpose to meet obligations arising from the company’s share-based incentive programme.
The share buy-back programme is executed pursuant to the so-called "Safe Harbour" provisions in Regulation (EU) No. 596/2014 of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016. The programme will end no later than on 30 September 2021.
The following transactions have been executed from 1 March to 5 March 2021:
| Number of shares | Average purchase price (DKK) | Transaction value (DKK) | |
| Accumulated, last announcement | 35,220 | 168.64 | 5,939,403 |
| 1 March 2021 2 March 2021 3 March 2021 4 March 2021 5 March 2021 | 500 300 200 300 300 | 193,65 206,91 202,15 196,92 196,13 | 96,825 62,073 40,430 59,076 58,839 |
| Accumulated under the programme | 36,820 | 6,256,646 |
A detailed overview of transactions executed during the period 1 March to 5 March 2021 is attached to this announcement.
Following the above transactions, MT Højgaard Holding A/S owns a total of 36,820 treasury shares, corresponding to 0.473% of the company’s total share capital.
Contact: CFO Martin Stig Solberg may be contacted by phone on +45 2270 9365
Attachments
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Teva Pharmaceutical Industries Ltd18.9.2026 22:32:00 CEST | Press release
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
Teva Pharmaceutical Industries Ltd18.9.2026 22:31:00 CEST | Press release
Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
Teva Pharmaceutical Industries Ltd18.9.2026 22:30:00 CEST | Press release
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
Leading Edge Materials Corp.18.9.2026 20:30:00 CEST | Press release
LEADING EDGE MATERIALS REPORTS QUARTERLY RESULTS TO JULY 31, 2026 AND ANNOUNCES CLOSING OF THE SECOND TRANCHE OF PRIVATE PLACEMENT
Orion Oyj18.9.2026 18:00:00 CEST | Press release
Orion Corporation: Acquisition of own shares during week 38, 2026
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
